Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the role of anti-VEGF therapies like aflibercept, ranibizumab, and off-label bevacizumab, and how treatment choices shift when affordability and access are limited.
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related…
Jean-Francois Korobelnik, MD, professor of ophthalmology, University Hospital of Bordeaux, explained findings of an analysis of the Phase 3 PULSAR trial designed to assess disease activity control. Dr…
In this episode of RetinUp, hosts John Kitchens, MD, and Scott Krzywonos discuss the new CMS GLOBE Model, a Medicare Part B drug pricing demonstration project, and the…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Diana Do, MD, professor of ophthalmology and vice chair for clinical affairs, Byers Eye Institute, Stanford University, discusses real-world data presented at the American Academy of Ophthalmology showing…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
